Amgen Q2 sales rise, but growth depends on Repatha and beyond

Amgen executives didn't shed a lot of light during the company's second quarter earnings conference call on issues at the top of investors' minds: commercial expectations for PCSK9 inhibitor Repatha (evolocumab) and the strategy for growth beyond existing research and development programs.

Amgen executives didn't shed a lot of light during the company's second quarter earnings conference call on issues at the top of investors' minds: commercial expectations for PCSK9 inhibitor Repatha (evolocumab) and the strategy for growth beyond existing research and development programs.

Thousand Oaks, California-based Amgen's growth strategy has become increasingly important, since revenues from its top-selling biologic Enbrel (etanercept) are growing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cardiovascular

More from Therapy Areas

PureTech’s New Spin-Off Wants Partners For Pulmonary Fibrosis Drug

 

Deupirfenidone hit its Phase II endpoint but the program remains risky and PureTech’s new Celea Therapeutics will aim to pull in extra funding for its late-stage development.

Xenon Nears Phase III Readout For Potential Epilepsy And Depression Blockbuster

 

Leading a field of rival potassium channel modulators, azetukalner will have a pivotal epilepsy readout early next year, with Phase III trials in depression and biopolar disorder also underway.

In Brief: Bayer Commits Up To $1.3bn For Kumquat’s KRAS G12D Inhibitor

 

Deal Snapshot: Bayer will take over development of the asset once Kumquat completes a Phase Ia clinical trial, but the biotech firm may opt in to share US profits and losses.